Dr. Esha Kaul

Dr. Esha Kaul

Haematology, Hemato-Oncology & Bone Marrow Transplant

Experience: Over 19 years

Medanta Hospital

Noida, India

Introduction

Dr. Esha Kaul, Director of Haemato-Oncology & BMT at Medanta Noida, treats blood cancers like leukemia and lymphoma, bone marrow failure conditions, and patients needing bone marrow or stem cell transplants when chemotherapy alone isn’t enough.

About Dr. Esha Kaul

Dr. Kaul has been dealing with blood cancers and marrow disorders for close to eighteen years now. Most patients coming to her either just got diagnosed with leukemia or lymphoma. What stands out about her is that she trained entirely in the American system. Dr. Kaul did her MBBS at AIIMS New Delhi, where she won the institute book prize.

Performs bone marrow transplants, including matched sibling donor transplants, haploidentical transplants, and unrelated donor transplants. Also involved in CAR-T cell therapy, which is one of the newest cancer treatments. She ranked first in the All India AFMC Entrance Examination back in 2001, which gives you an idea of how sharp she was even before medical school started.

Qualifications

  • MBBS — All India Institute of Medical Sciences (AIIMS), New Delhi (2006)
  • Residency (Internal Medicine) — Tufts University, Boston, USA (2011)
  • Fellowship (Hematology-Oncology) — Tufts University, Boston, USA (2014)
  • Dual American Board Certification — Internal Medicine & Haematology

Awards & Recognition

  • Director of Haemato-Oncology & BMT at Medanta Noida.
  • Dual American Board Certified in Internal Medicine and Haematology.
  • Built and established transplant programs at Jaypee Hospital, Max Hospital, and BLK Super Speciality Hospital.
  • Abstract Achievement Award — American Society of Hematology (2013).
  • Travel Grant — International Society of Amyloidosis (2014).
  • Institute Book Prize — AIIMS New Delhi.
  • Rank 1 — All India AFMC Entrance Examination (2001).

Specialities & Expertise

  • Bone marrow transplantation
  • Stem cell transplant, including haploidentical and unrelated donors
  • Leukemia and lymphoma treatment
  • Multiple myeloma management
  • Aplastic anemia treatment
  • CAR-T cell therapy
  • Complex blood disorder management
  • Post-transplant care and rejection management

Patient Experience & Approach

Patients say Dr. Kaul sits down and explains what blood cancer actually means because most families hear the word leukemia and immediately think it’s the end. Those whose family members went through haploidentical transplants say she managed the whole process carefully. Parents of young leukemia patients appreciate that she explains the treatment roadmap from induction chemo through maintenance in simple language, so they know what the next six months to two years look like.